These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 33357364)

  • 21. Overlap in the neural circuitry and molecular mechanisms underlying ketamine abuse and its use as an antidepressant.
    Kokane SS; Armant RJ; Bolaños-Guzmán CA; Perrotti LI
    Behav Brain Res; 2020 Apr; 384():112548. PubMed ID: 32061748
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Residual symptoms in depression an emerging therapeutic concept.
    Sonino N; Fava GA
    Prog Neuropsychopharmacol Biol Psychiatry; 2002 May; 26(4):763-70. PubMed ID: 12188108
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Novel agents in development for the treatment of depression.
    Grady MM; Stahl SM
    CNS Spectr; 2013 Dec; 18 Suppl 1():37-40; quiz 41. PubMed ID: 24252548
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dysfunctional astrocytic regulation of glutamate transmission in a rat model of depression.
    Gómez-Galán M; De Bundel D; Van Eeckhaut A; Smolders I; Lindskog M
    Mol Psychiatry; 2013 May; 18(5):582-94. PubMed ID: 22371047
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Bidirectional Homeostatic Regulation of a Depression-Related Brain State by Gamma-Aminobutyric Acidergic Deficits and Ketamine Treatment.
    Ren Z; Pribiag H; Jefferson SJ; Shorey M; Fuchs T; Stellwagen D; Luscher B
    Biol Psychiatry; 2016 Sep; 80(6):457-468. PubMed ID: 27062563
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Emerging treatment mechanisms for depression: focus on glutamate and synaptic plasticity.
    Gerhard DM; Wohleb ES; Duman RS
    Drug Discov Today; 2016 Mar; 21(3):454-64. PubMed ID: 26854424
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Fatty acid metabolism and its longitudinal relationship with the hypothalamic-pituitary-adrenal axis in major depression: Associations with prospective antidepressant response.
    Mocking RJ; Verburg HF; Westerink AM; Assies J; Vaz FM; Koeter MW; Ruhé HG; Schene AH
    Psychoneuroendocrinology; 2015 Sep; 59():1-13. PubMed ID: 26010860
    [TBL] [Abstract][Full Text] [Related]  

  • 28. PCLO rs2522833 modulates HPA system response to antidepressant treatment in major depressive disorder.
    Schuhmacher A; Mössner R; Höfels S; Pfeiffer U; Guttenthaler V; Wagner M; Schwab SG; Maier W; Zobel A
    Int J Neuropsychopharmacol; 2011 Mar; 14(2):237-45. PubMed ID: 20701824
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Glutamate hypothesis of depression and its consequences for antidepressant treatments.
    Musazzi L; Treccani G; Popoli M
    Expert Rev Neurother; 2012 Oct; 12(10):1169-72. PubMed ID: 23082730
    [No Abstract]   [Full Text] [Related]  

  • 30. Novel Glutamatergic Modulators for the Treatment of Mood Disorders: Current Status.
    Henter ID; Park LT; Zarate CA
    CNS Drugs; 2021 May; 35(5):527-543. PubMed ID: 33904154
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ketamine and rapid-acting antidepressants: a window into a new neurobiology for mood disorder therapeutics.
    Abdallah CG; Sanacora G; Duman RS; Krystal JH
    Annu Rev Med; 2015; 66():509-23. PubMed ID: 25341010
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A review of ketamine in affective disorders: current evidence of clinical efficacy, limitations of use and pre-clinical evidence on proposed mechanisms of action.
    Naughton M; Clarke G; O'Leary OF; Cryan JF; Dinan TG
    J Affect Disord; 2014 Mar; 156():24-35. PubMed ID: 24388038
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tumor necrosis factor-mediated downregulation of spinal astrocytic connexin43 leads to increased glutamatergic neurotransmission and neuropathic pain in mice.
    Morioka N; Zhang FF; Nakamura Y; Kitamura T; Hisaoka-Nakashima K; Nakata Y
    Brain Behav Immun; 2015 Oct; 49():293-310. PubMed ID: 26116449
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Astroglial connexin 43 sustains glutamatergic synaptic efficacy.
    Chever O; Pannasch U; Ezan P; Rouach N
    Philos Trans R Soc Lond B Biol Sci; 2014 Oct; 369(1654):20130596. PubMed ID: 25225090
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Astrocytic Glutamatergic Transmission and Its Implications in Neurodegenerative Disorders.
    Satarker S; Bojja SL; Gurram PC; Mudgal J; Arora D; Nampoothiri M
    Cells; 2022 Mar; 11(7):. PubMed ID: 35406702
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacological properties of glutamatergic drugs targeting NMDA receptors and their application in major depression.
    Serafini G; Pompili M; Innamorati M; Dwivedi Y; Brahmachari G; Girardi P
    Curr Pharm Des; 2013; 19(10):1898-922. PubMed ID: 23173582
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Xiaoyaosan exerts antidepressant-like effects by regulating the functions of astrocytes and EAATs in the prefrontal cortex of mice.
    Liu Y; Ding XF; Wang XX; Zou XJ; Li XJ; Liu YY; Li J; Qian XY; Chen JX
    BMC Complement Altern Med; 2019 Aug; 19(1):215. PubMed ID: 31412844
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Synaptic P2X7 receptor regenerative-loop hypothesis for depression.
    Bennett MR
    Aust N Z J Psychiatry; 2007 Jul; 41(7):563-71. PubMed ID: 17558618
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The NMDA receptor as a therapeutic target in major depressive disorder.
    Pittenger C; Sanacora G; Krystal JH
    CNS Neurol Disord Drug Targets; 2007 Apr; 6(2):101-15. PubMed ID: 17430148
    [TBL] [Abstract][Full Text] [Related]  

  • 40. GluN2B-containing NMDA receptors regulate depression-like behavior and are critical for the rapid antidepressant actions of ketamine.
    Miller OH; Yang L; Wang CC; Hargroder EA; Zhang Y; Delpire E; Hall BJ
    Elife; 2014 Oct; 3():e03581. PubMed ID: 25340958
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.